Fluproquazone: analgesic activity in outpatients with non-migrainous headache.
The analgesic activity of 4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone (fluproquazone) was investigated in three separate controlled studies including 131 outpatients with non-migrainous headache. By means of the patients' self-assessment of pain intensity and pain relief, 25 mg and 50 mg doses were shown to be effective according to some parameters of analgesic effect; a 100-mg dose was more effective, being significantly different from placebo for all parameters of analgesia. Fluproquazone 50 mg was as active as acetylsalicylic acid 1000 mg and slightly less active than a combination of propyphenazone 220 mg and allobarbital 30 mg. Except for the occurrence of vomiting in one patient after fluproquazone 50 mg and 100 mg. the drug was well tolerated.
D000328:Adult; D000368:Aged; D000700:Analgesics; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011799:Quinazolines / Q000627:therapeutic use*; D052999:Quinazolinones; D013997:Time Factors
D000700:Analgesics; D010919:Placebos; D011799:Quinazolines; D052999:Quinazolinones; D001241:Aspirin; C023491:fluproquazone